Clinical Microbiology and Antimicrobial Chemotherapy. 2010; 12(1):54-56
This study was performed to evaluate a potential of ribavirin for inhibiting Batai virus replication in vitro. Ribavirin manufactured by ICN Switzerland AG (Switzerland) was used for the study. The drug and specific immune ascitic fluid were added to a cell culture (Vero E6)1 hour after the virus-to-cell contact at 37 °C. Ribavirin was also added 1 hour before and 2, 4, 6 and 18 hours after the virus-cell contact. This study first showed that ribavirin significantly inhibited Batai virus replication in vitro.